Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)

2026-02-20 16:00:27 ET

The last time I spoke about Vera Therapeutics, Inc. ( VERA ), it was in a Seeking Alpha article entitled " Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients ." At that time, I mentioned that the results from the phase 3 ORIGIN trial using the dual BAFF/APRIL inhibitor atacicept for the treatment of patients with immunoglobulin A nephropathy [IgAN] were to be released in 2025. I was bullish on the prospects and had placed a Strong Buy rating on this stock based on its potential to do well because it had deployed a dual targeting mechanism....

Read the full article on Seeking Alpha

For further details see: